Related Experiment Video
Updated: Dec 13, 2025
Candida albicans Biofilm Development on Medically-relevant Foreign Bodies in a Mouse Subcutaneous Model Followed by Bioluminescence Imaging
Published on: January 27, 2015
Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model
M Ghannoum1,2, N Isham3, D Angulo4
1Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA mahmoud.ghannoum@case.edu.
Abstract:
Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris fungal burden in infected animals compared with untreated controls. This indicates promise for use of IBX in controlling skin infection and colonization of hospitalized patients.
Insights
Ibrexafungerp (IBX) shows promise in treating skin infections caused by Candida auris. This antifungal agent significantly reduced fungal burden and lesion severity in a guinea pig model, suggesting potential for hospitalized patients.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Pharmacology
Background:
- Candida auris poses a significant risk for skin colonization in hospital settings, potentially driving nosocomial infections.
- Effective treatments are needed to manage C. auris skin burden and prevent its spread in healthcare environments.
Purpose of the Study:
- To evaluate the efficacy of ibrexafungerp (IBX) in a preclinical skin model of Candida auris infection.
- To assess the impact of IBX on clinical signs, fungal burden, and tissue histology in a guinea pig model.
Main Methods:
- A guinea pig model was utilized to simulate Candida auris skin colonization.
- Animals received oral dosing of 10 mg/kg ibrexafungerp (IBX).
- Evaluations included clinical appearance, tissue fungal burden, histology, and pharmacokinetics.
Main Results:
- Oral ibrexafungerp (IBX) treatment significantly reduced the severity of skin lesions.
- A substantial decrease in Candida auris fungal burden within infected tissues was observed in IBX-treated animals compared to controls.
- Pharmacokinetic and histological data supported the observed antifungal effects.
Conclusions:
- Ibrexafungerp (IBX) demonstrates significant potential for controlling Candida auris skin infections and colonization.
- These findings support the investigation of IBX as a therapeutic option for hospitalized patients at risk of C. auris skin colonization.
More Related Videos
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021